Premaitha Health PLC Issue of Equity (8871W)
February 15 2017 - 1:00AM
UK Regulatory
TIDMNIPT
RNS Number : 8871W
Premaitha Health PLC
15 February 2017
Premaitha Health plc
("Premaitha" or the "Company")
Issue of Equity
Manchester, UK - 15 February 2017: Premaitha Health plc (AIM:
NIPT), developer of a leading CE-marked non-invasive prenatal
screening system, announces that it has agreed to issue to Harwood
Capital ("Harwood") 17,000,000 new ordinary shares of 0.1 pence per
share, subject to admission to AIM, raising GBP1,487,500 at a price
of 8.75 pence per share. Following the allotment of the shares,
Harwood's holding will represent 6.9% of the issued ordinary share
capital of Premaitha.
The Company's 17,000,000 new ordinary shares of 0.1p each are
expected to be admitted to trading on AIM ("Admission") at 8:00
a.m. on 20 February 2017.
Following Admission, the Company's total issued and voting share
capital will comprise 245,163,709 ordinary shares of 0.1p each.
This figure may be used by shareholders as the denominator for the
calculations by which they determine if they are required to notify
their interest in, or a change to their interest in, the
Company.
Adam Reynolds, Chairman, commented:
"We are delighted that a fund of Harwood's quality has
identified the opportunity in Premaitha. Their investment follows
evidence of further traction with the IONA(R) test in key markets
and the recent announcement of our conditional acquisition of
Taiwan-based Yourgene Bioscience, which brings expanded market
access into Asia - the fastest growing market for non-invasive
prenatal testing."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For more information, please contact:
Premaitha Health plc Tel: +44 (0)
161 667 6865
Dr Stephen Little, Chief Executive
Officer
Barry Hextall, Chief Financial
Officer
investors@premaitha.com
Cairn Financial Advisers LLP (Nomad) Tel: +44 (0)
20 7213 0880
Liam Murray / Jo Turner
finnCap Tel: +44 (0)
20 7220 0500
Adrian Hargrave / Scott Mathieson
(Corporate Finance)
Tony Quirke (Corporate Broking)
Vigo Communications Tel: +44 (0)
20 7830 9700
Ben Simons / Fiona Henson / Antonia
Pollock
premaitha@vigocomms.com
About Premaitha
Premaitha is a molecular diagnostics company which uses the
latest advances in DNA analysis technology to develop safer, faster
and regulatory approved non-invasive screening tests for pregnant
women.
Premaitha's lead test - the IONA(R) test - was launched in
February 2015 and is the leading CE marked complete system which
estimates the risk of a fetus being affected with Down's syndrome
or other genetic conditions. The IONA(R) test is performed on the
mother's blood sample - which contains traces of fetal DNA - and
then analysed using next generation DNA sequencing technology from
ThermoFisher Scientific.
Unlike existing prenatal screening methods, due to its high
level of accuracy, the IONA(R) test can significantly reduce the
number of women subjected to unnecessary stressful and invasive
follow up diagnostic procedures which are costly, resource
intensive and carry a risk of miscarriage.
Non-invasive prenatal screening is an emerging, multi-billion
dollar global market and Premaitha's complete CE Marked system
enables laboratories and health care practitioners to offer an
approved, non-invasive prenatal screening system in-house.
Premaitha is based in Manchester Science Park, United Kingdom
and its shares trade on the AIM market of the London Stock Exchange
(AIM: NIPT). For further information please visit
www.premaitha.com. Follow us on twitter @PremaithaHealth.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEDZLFFDLFBBBK
(END) Dow Jones Newswires
February 15, 2017 02:00 ET (07:00 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From May 2023 to May 2024